… the approval of biosimilars differs from that of original drug products [14… Patients who had
previously received anti-TNF therapy … comparable rates and characteristics of infusion reactions …

… 2016 the US Food and Drug Administration (FDA) registered biosimilar infliximab for all …
countries employ demand-side incentives to encourage the uptake of biosimilars. In the US, …

… of lower-priced biosimilar versions of anti-TNF may lead to a … Corresponding price reductions
may force pharmaceutical … included various aspects of the market entry of a biosimilar, …

… biosimilar drug, extensive comparability exercises, including physicochemical characteristics
… ): A total of 459 patients were naïve to anti-TNF-α therapy, 196 had a previous exposure to …

… with IBD has increased, biosimilars have become available, … drug, commercialized as
Remicade ® , was the first anti-TNF … characteristics are known to predict response to anti-TNF …

… Anti- tumor Necrosis Factor (anti-TNF) agents are the … were receiving the reference drug
or the biosimilar. Citation66 … on the common aspects between biosimilars and biological RPs …

… review and meta-analysis, we aimed to assess the clinical efficacy and safety of biosimilar of
anti-TNF-… Characteristics of observational studies of biosimilar of anti-tumour necrosis factor-…

… be proven in terms of their characteristics, biological activity, … involving the reference
drug[8]. Indeed, approval to use the … and the biosimilar infliximab (CT-P13) in 250 anti-TNF-naive …

… adapted to the characteristics of each database consulted, … lists of the articles that were
selected for the review. Likewise, … patients were treated with biosimilars such as Inflectra (ST8), …

… relevant to the mechanism of action of the drug. For anti-tumour necrosis factor [TNF]-…
anti-TNF levels, reduced efficacy, and side-effects including allergic reactions. A systematic review …